Therapeutics case studies

Learn more on how we bring life changing therapies to market.

Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.

Re-adjudicating a respiratory and cardiovascular trial during COVID-19

The FDA advised the trial to re-adjudicate so that the study accounted for the effects of COVID-19 on the trial outcomes. To ensure that the trial data would be submitted to the FDA as scheduled, ICON needed to coordinate re-adjudication of 700 endpoints within a compressed three-month timeline.

Allergic rhinitis

A Biotech client contracted ICON to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.

Rapid mobilisation to advance COVID-19 treatment development

In February 2020 ICON quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.

Rapid manuscript development and delivery

Through close collaboration with a client, the ICON team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.

H1N1 vaccine study

A sponsor approached ICON during an influenza pandemic in Mexico to conduct a randomised, placebo controlled vaccine study with an investigative pandemic H1N1 vaccine.

Exceeding recruitment timelines

ICON was awarded a global study for Major Depressive Disease (MDD) in over 600 adult subjects. Enrollment began during the COVID pandemic and despite challenging protocol requirements, IMP expiry date and database lock requirements, ICON reached LPR and DBL closed five months early.

Rapid mobilisation to advance COVID-19 vaccine development

COA Repository, revolutionizing the management of COAs within the sponsor’s clinical trials.

Agile operations drive enrollment in COVID-19 treatment studies

ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.

Overcoming the challenges of COVID-19 clinical trial conditions

A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.

Digital solutions for an evolving COVID-19 environment

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.